{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:11:55Z","timestamp":1761664315759,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and technology commission","doi-asserted-by":"crossref","award":["Z201100005420012"],"award-info":[{"award-number":["Z201100005420012"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Hospital Authority","award":["ZYLX201802"],"award-info":[{"award-number":["ZYLX201802"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The outbreak of coronavirus disease 2019 (COVID-19) posed an enormous threat to public health. The use of antiviral drugs in patients with this disease have triggered people\u2019s attentions. Whether interferon alfa-2b or lopinavir\/ritonavir (LPV\/r) plus interferon alfa-2b treatment can against SARS-CoV-2 was unknown. The objectives of this study was to evaluate the efficacy and safety of interferon alfa-2b and LPV\/r plus interferon alfa-2b for SARS-CoV-2 infection in adult patients hospitalized with COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospective cohort study of 123 patients confirmed SARS-CoV-2 infection by PCR on nasopharyngeal swab and symptoms between Jan. 13 and Apr. 23, 2020. All patients received standard supportive care and regular clinical monitoring. Patients were assigned to standard care group (n\u2009=\u200912), interferon alfa-2b group (n\u2009=\u200944), and combination LPV\/r plus interferon alfa-2b group (n\u2009=\u200967). The primary endpoints were duration of required oxygen support and virus clearance time. Associations between therapies and these outcomes were assessed by Cox proportional hazards regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Baseline clinical characteristics were not significantly different among the three groups (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). No significant associations were observed between LPV\/r\/interferon alfa-2b and faster SARS-CoV-2 RNA clearance (HR, 0.85 [95% confidence interval (CI) 0.45\u20131.61]; <jats:italic>P<\/jats:italic>\u2009=\u20090.61 in interferon alfa-2b group vs HR, 0.59 [95% CI 0.32\u20131.11]; <jats:italic>P<\/jats:italic>\u2009=\u20090.10 in LPV\/r plus interferon alfa-2b group). Individual therapy groups also showed no significant association with duration of required oxygen support. There were no significant differences among the three groups in the incidence of adverse events (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with confirmed SARS-CoV-2 infection, no benefit was observed from interferon alfa-2b or LPV\/r plus interferon alfa-2b treatment. The findings may provide references for treatment guidelines of patients with SARS-CoV-2 infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06595-6","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T09:03:56Z","timestamp":1630314236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir\/ritonavir plus interferon alfa-2b against SARS-CoV-2"],"prefix":"10.1186","volume":"21","author":[{"given":"Jingyuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunjing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haofeng","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1478-3072","authenticated-orcid":false,"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"issue":"10223","key":"6595_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497\u2013506.","journal-title":"The Lancet"},{"issue":"20","key":"6595_CR2","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052.","journal-title":"JAMA"},{"issue":"16","key":"6595_CR3","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jama.2020.5394","volume":"323","author":"G Grasselli","year":"2020","unstructured":"Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574.","journal-title":"JAMA"},{"issue":"6","key":"6595_CR4","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.ejso.2020.04.031","volume":"46","author":"AO Joseph","year":"2020","unstructured":"Joseph AO, Joseph JP, Pereira B, Gahir J. Coronavirus outbreak: reorganising the breast unit during a pandemic. Eur J Surg Oncol. 2020;46(6):1176\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"6595_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1152\/physiolgenomics.00033.2020","volume":"52","author":"RM Golonka","year":"2020","unstructured":"Golonka RM, Saha P, Yeoh BS, Chattopadhyay S, Gewirtz AT, Joe B, Vijay-Kumar M. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease. Physiol Genomics. 2020;52(5):217\u201321.","journal-title":"Physiol Genomics"},{"key":"6595_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/irv.12758","volume":"14","author":"J Lian","year":"2020","unstructured":"Lian J, Jin X, Hao S, Jia H, Cai H, Zhang X, Hu J, Zheng L, Wang X, Zhang S, et al. Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. Influenza Other Respir Viruses. 2020;14:564\u201374.","journal-title":"Influenza Other Respir Viruses"},{"issue":"5","key":"6595_CR7","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/jth.14820","volume":"18","author":"D Arachchillage","year":"2020","unstructured":"Arachchillage D, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(5):1233\u20134.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"6595_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13054-020-02924-4","volume":"24","author":"FS Cardoso","year":"2020","unstructured":"Cardoso FS, Pereira R, Germano N. Liver injury in critically ill patients with COVID-19: a case series. Crit Care. 2020;24(1):190.","journal-title":"Crit Care"},{"issue":"6","key":"6595_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/phar.2410","volume":"40","author":"KM Johnson","year":"2020","unstructured":"Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE. Managing COVID-19 in renal transplant recipients: a review of recent literature and case supporting corticosteroid-sparing immunosuppression. Pharmacotherapy. 2020;40(6):517\u201324.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"6595_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","volume":"31","author":"F Chen","year":"2004","unstructured":"Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, Cheng VC, Tsui WH, Hung IF, Lee TS, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69\u201375.","journal-title":"J Clin Virol"},{"issue":"6","key":"6595_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","volume":"67","author":"JF Chan","year":"2013","unstructured":"Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606\u201316.","journal-title":"J Infect"},{"issue":"7","key":"6595_CR12","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/jac\/dkv085","volume":"70","author":"S Shalhoub","year":"2015","unstructured":"Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N, Mushtaq A. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70(7):2129\u201332.","journal-title":"J Antimicrob Chemother"},{"issue":"19","key":"6595_CR13","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"6595_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","volume":"39","author":"R Channappanavar","year":"2017","unstructured":"Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529\u201339.","journal-title":"Semin Immunopathol"},{"issue":"6","key":"6595_CR15","doi-asserted-by":"publisher","first-page":"e12465","DOI":"10.15252\/emmm.202012465","volume":"12","author":"E Andreakos","year":"2020","unstructured":"Andreakos E, Tsiodras S. COVID-19: lambda interferon against viral load and hyperinflammation. EMBO Mol Med. 2020;12(6):e12465.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"6595_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","volume":"19","author":"R Channappanavar","year":"2016","unstructured":"Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181\u201393.","journal-title":"Cell Host Microbe"},{"key":"6595_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijid.2013.12.003","volume":"20","author":"JA Al-Tawfiq","year":"2014","unstructured":"Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42\u20136.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"6595_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"H Lu","year":"2020","unstructured":"Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69\u201371.","journal-title":"Biosci Trends"},{"issue":"5","key":"6595_CR19","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s00134-020-06022-5","volume":"46","author":"W Alhazzani","year":"2020","unstructured":"Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854\u201387.","journal-title":"Intensive Care Med"},{"issue":"11","key":"6595_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","volume":"14","author":"AS Omrani","year":"2014","unstructured":"Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, Almakhlafi GA, Albarrak MM, Memish ZA, Albarrak AM. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090\u20135.","journal-title":"Lancet Infect Dis"},{"key":"6595_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.msard.2016.05.005","volume":"8","author":"SM Dalbjerg","year":"2016","unstructured":"Dalbjerg SM, Tsakiri A, Frederiksen JL. Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis\u2014a case report. Mult Scler Relat Disord. 2016;8:93\u20135.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"6595_CR22","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.transproceed.2014.05.065","volume":"46","author":"SA Dos","year":"2014","unstructured":"Dos SA, Guardia AC, Pereira TS, Ataide EC, Mei M, Udo ME, Boin IF, Stucchi RS. Rhabdomyolysis as a clinical manifestation of association with ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-alpha in liver-transplanted patients: a case report and literature review. Transplant Proc. 2014;46(6):1887\u20138.","journal-title":"Transplant Proc"},{"issue":"6","key":"6595_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00011-020-01342-0","volume":"69","author":"J Yuan","year":"2020","unstructured":"Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, Liang Y, Ding X, Tan G, Tang S, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res. 2020;69(6):599\u2013606.","journal-title":"Inflamm Res"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06595-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06595-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06595-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T09:05:09Z","timestamp":1630314309000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06595-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6595"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06595-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"27 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical study was conducted in compliance with the ethical principles of the Declaration of Helsinki and its later amendments. The Ethics Committee of Beijing Ditan Hospital approved our study protocol [Approval no. 2020(014)-01]. The data used in this study was anonymised before its use.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"885"}}